Recombinant adenoassociated viral vectors are versatile and promising tools for somatic gene therapy, with ongoing research focused on manufacturing and clinical translation.
Several gene delivery vehicles are being developed for somatic gene therapy and each of these vectors has unique properties which makes them appropriate for different human disease applications.Recombinant adenoassociated viral (rAAV) vectors are proving themselves to be safe and ef®cacious for the long-term expression of proteins and correction of genetic diseases following a single administration.The increasing number of tissues and diseases being targeted with rAAV vectors demonstrates their versatility and has resulted in different approaches for enhancing vector performance.Improving the methods for large-scale manufacturing, and accumulating safety and ef®cacy data in animals and humans are areas of intense research.
No takes yet. Share an insight, caveat, or question.
Richard O. Snyder (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: